Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How Broad Labels May Make Market Access In Germany More Difficult

Executive Summary

Companies might have to rethink their German market access strategies if new legislation is passed to informs doctors of the outcome of AMNOG benefit assessments.

You may also be interested in...

Politics Dilute Germany’s AMNOG Updates: Impact On Pharma Firms

New updates to Germany’s 2011 AMNOG healthcare reform act could lead to more conservative prescribing and benefit assessments for older products. Pricing measures were dropped but will likely resurface after September’s general elections.

Germany Cancels Confidential Drug Pricing

Plans to make pharmaceutical prices in Germany confidential are likely to be shelved, but other measures could help companies better navigate price transparency.

Advanced Therapies: Payment Revolution Must Accompany Industrial Revolution In Europe

The advanced therapies sector is undergoing something of an industrial revolution, but access issues for products coming to market remain, says Miguel Forte, CEO of Bone Therapeutics. However, there are opportunities to create a better environment for the sector, including regulatory change and more harmonization of HTA processes.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts